Quantitative analyses of DAPK1 methylation in AML and MDS

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages

  Claus, Rainer ^a   Hackanson, Björn ^b   Poetsch, Anna R ^a   Zucknick, Manuela ^a   Sonnet, Miriam ^a   Blagitko Dorfs, Nadja ^b   Hiller, Jan ^b   Wilop, Stefan ^c   Brümmendorf, Tim H ^c   Galm, Oliver ^c   Platzbecker, Uwe ^d   Byrd, John C ^e   Döhner, Konstanze ^f   Döhner, Hartmut ^f   Lübbert, Michael ^b   Plass, Christoph ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF ULM   (Germany)

Author keywords

AML; DAPK1; DNA methylation; epigenetics; translational research

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH ASSOCIATED PROTEIN KINASE 1 GENE; DNA METHYLATION; EPIGENETICS; FEMALE; GENE FREQUENCY; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRANSCRIPTION REGULATION; TRANSLATIONAL RESEARCH; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; BONE MARROW CELLS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; COHORT STUDIES; DNA METHYLATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 84861581070     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26429     Document Type: Article

References (20)

1. Esteller M,. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-59.
2. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, et al., DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13-27.
3. Plass C, Yu F, Yu L, Strout MP, El-Rifai W, Elonen E, Knuutila S, Marcucci G, Young DC, Held WA, Bloomfield CD, Caligiuri MA,. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene 1999; 18: 3159-65.
4. Bullinger L, Ehrich M, Dohner K, Schlenk RF, Dohner H, Nelson MR, van den Boom D,. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010; 115: 636-42.
5. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007; 129: 879-90.
6. Katzenellenbogen RA, Baylin SB, Herman JG,. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999; 93: 4347-53.
7. Greco M, D'Alo F, Scardocci A, Criscuolo M, Fabiani E, Guidi F, Di Ruscio A, Migliara G, Pagano L, Fianchi L, Chiusolo P, Hohaus S, et al., Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol Dis 2010; 45: 181-5.
8. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB,. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6.
9. Clark SJ, Harrison J, Paul CL, Frommer M,. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22: 2990-7.
10. Tost J, Dunker J, Gut IG,. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 2003; 35: 152-6.
11. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D,. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005; 102: 15785-90.
12. Aggerholm A, Hokland P,. DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology? Blood 2000; 95: 2997-9.
13. Aggerholm A, Guldberg P, Hokland M, Hokland P,. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res 1999; 59: 436-41.
14. Voso MT, Scardocci A, Guidi F, Zini G, Di Mario A, Pagano L, Hohaus S, Leone G,. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 2004; 103: 698-700.
15. Brakensiek K, Langer F, Kreipe H, Lehmann U,. Low level of DAP-kinase DNA methylation in myelodysplastic syndrome. Blood 2004; 104: 1586-7; author reply 87-8.
16. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H,. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002; 160: 605-12.
17. Galm O, Wilop S, Luders C, Jost E, Gehbauer G, Herman JG, Osieka R,. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol 2005; 84 (Suppl 1): 39-46.
18. Qian J, Yao DM, Lin J, Wang YL, Han LX, Xu WR, Wu CY,. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome. Int J Lab Hematol 2008; 32: 74-81.
19. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, et al., Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114: 2764-73.
20. Wu X, Liu W, Tian Y, Xiao M, Wu Y, Li C,. Aberrant methylation of death-associated protein kinase 1 CpG islands in myelodysplastic syndromes. Acta Haematol 2011; 125: 179-85.